A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome.

ABSTRACT:

Objective

Individual sensitivity to recombinant human GH (r-hGH) is variable. Identification of genetic factors contributing to this variability has potential use for individualization of treatment. The objective of this study was to identify genetic markers and gene expression profiles associated with growth response on r-hGH therapy in treatment-naïve, prepubertal children with GH deficiency (GHD) or Turner syndrome (TS).

Design

A prospective, multicenter, international, open-label pharmacogenomic study.

Methods

The associations of genotypes in 103 growth- and metabolism-related genes and baseline gene expression profiles with growth response to r-hGH (cm/year) over the first year were evaluated. Genotype associations were assessed with growth response as a continuo

SUBMITTER: Clayton P 

PROVIDER: S-EPMC3731924 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature